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ABSTRACT
DETECTING MUTATIONS RELATED TO ANTIBIOTIC RESISTANCE IN
PSEUDOMONAS AERUGINOSA
by Neda Nemat-Gorgani
Excessive use of broad-spectrum antibiotics in hospitals has led to the emergence
of highly resistant strains of Pseudomonas aeruginosa. To reduce the selection pressure
for resistance, it is important to determine the antibiotic-susceptibility pattern of bacteria
so that hospital patients can be treated with more narrow-spectrum and target-specific
antibiotics. This study describes the development of a technique for detecting point
muations in the fluoroquinolone resistance-determining region of the gyrA and parC
genes as well as the efflux regulatory genes mexR, mexZ, and mexOZ that are associated
with fluoroquinolone and aminoglycoside resistance. The assay is based on a short
DNA-sequencing method using multiplex-fast polymerase chain reaction (PCR) and
Pyrosequencing™ for amplification and sequencing of the selected genes. Fifty-nine
clinical isolates of P. aeruginosa were examined for mutations in the above-mentioned
genes. Mutations related to antibiotic resistance were detected in codons 83 and 87 of
gyrA and codon 126 of the mexR regulatory gene. Results of this study suggest
Pyrosequencing™ as a substitute for traditional methods, as it provides a rapid and
reliable technique for determining the antibiotic-resistance pattern of a given bacterial
strain in < 1 h.
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PREFACE
This thesis is organized in three chapters. Chapter I presents a general
introduction on Pseudomonas aeruginosa and its resistance to antibiotics and the aim of
the research study. Chapter II describes the mechanisms of antibiotic resistance in P.
aeruginosa. Chapter III includes the details of the study, prepared as a manuscript
entitled "Detection of point mutations associated with antibiotic resistance in
Pseudomonas aeruginosa" (submitted to the Journal of Microbiological Methods).
The last part of the thesis is composed of appendixes, which provides additional
details about the data collected.
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CHAPTER I
INTRODUCTION
Pseudomonas aeruginosa is a notorious opportunistic pathogen and is isolated
mostly from patients with urinary tract infections, wound infections, and severe burns. P.
aeruginosa infection is also known to be a serious problem in patients hospitalized with
cystic fibrosis, cancer, and burns. Half of these infections are fatal. P. aeruginosa has
been considered a nosocomial pathogenic bacterium in a number of studies. What makes
P. aeruginosa infections problematic is the bacterium's resistance to antibiotics and
disinfectants (Lambert, 2002). Antibiotic and disinfectant resistance have been attributed
to 1) intrinsic resistance to a wide variety of antimicrobial agents due to low membrane
permeability, 2) genetic capacity to express a wide range of resistance mechanisms, 3)
acquisition of resistance to antibiotics through chromosomal mutations, and 4)
acquisition of resistance genes from other organisms via plasmids, bacteriophages, and/or
transposons (Lambert, 2002).
P. aeruginosa is an extremely adaptive organism. It can grow on a wide range of
substrates and quickly responds to environmental alterations (Lambert, 2002). It has a
large genome (6.26 Mbp encoding 5,567 genes) compared to other common human
opportunistic pathogens such as Escherichia coli K12 (4.64 Mbp), Haemophilus influenzae
(1.83 Mbp encoding 1,714 genes), and Staphylococcus aureus N315 (2.81 Mbp encoding
2,594 genes) (Lambert, 2002). P. aeruginosa consequently possesses substantial
additional genetic capacity compared to other bacteria. This capacity may confer its
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extremely adaptive nature, including the capacity to develop resistance when antibiotics
are employed extensively (Lambert, 2002).
Mechanisms of resistance to antibiotics in P. aeruginosa are either based on nonmutational intrinsic resistance or mutational acquired resistance. Fluoroquinolones and
aminoglycosides are two important classes of antibiotics used in the treatment of
Pseudomonas infections. Pseudomonas readily develops resistance to these agents,
reducing the antibiotic effectiveness.
In this study, we developed a DNA-based technique to determine the antibioticresistance pattern of P. aeruginosa in a shorter period of time compared with traditional
methods such as disk diffusion or agar dilution. We used multiplex polymerase chain
reaction (PCR) and Sanger sequencing to find key mutations in the gyrA, mexR, parC,
mexZ, and mexOZ genes of P. aeruginosa isolates exhibiting resistance to
fluoroquinolones and aminoglycosides. Furthermore, Pyrosequencing™ was used as the
ultimate method to detect specific point mutations in the above-mentioned genes.
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CHAPTER II
MECHANISMS OF ANTIBIOTIC RESISTANCE IN PSEUDOMONAS AERUGINOSA
This section reviews the resistance of P. aeruginosa to antibiotics and
antimicrobial agents based on non-mutational intrinsic resistance and mutational acquired
resistance.

1. Non-mutational intrinsic resistance
P. aeruginosa has natural resistance to many antimicrobial agents. This is
primarily due to active efflux systems that are present in all wild-type strains, its
membrane permeability properties, and plasmid and chromosomal pMactamase genes
(Aires et al., 1999, Giwercman et al., 1990, Lambert, 2002, Livermore, 2002).
The most well-known efflux system that leads to intrinsic antibiotic resistance is
the MexAB-oprM system. Efflux pumps are active transporters that are localized in the
cytoplasmic membrane of all bacterial strains and reduce the antibiotic levels at the site
of activity in the cell. Antibiotics are the most clinically important substrates of efflux
systems. The MexAB-oprM efflux system is expressed constitutively in wild-type strains
of P. aeruginosa and confers resistance to a broad range of drugs including quinolones,
chloramphenicol, P-lactam, P-lactam inhibitors, trimetoprime, sulfamethoxasole,
tetracycline, and novobiocin (Aires et al., 1999).
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2. Mutational acquired resistance
P. aeruginosa acquires resistance to antibiotics through chromosomal mutations.
These mutations include 1) mutations in the regulatory genes for the drug efflux pump
systems, 2) mutations in the target genes encoding DNA gyrase (gyrA) and
topoisomerase IV (parC), 3) mutations causing cell wall impermeability due to loss of
OprD, a porin that forms narrow transmembrane channels, 4) mutations causing
alterations in penicillin-binding proteins, and 5) impulsive mutations in the regulatory
genes for the bacteria's P-lactamase resulting in derepression of P-lactamase.

2.1. Derepression of P-lactamase
Chromosomally encoded p-lactamase is increasingly proven as a cause of
resistance to novel p-lactam antibiotics (Giwercman et al., 1990). All strains of P.
aeruginosa express a chromosomal AmpC P-lactamase. In the absence of P-lactam
antibiotics, this enzyme is expressed at a very low basal level but can increase to much
higher levels in the presence of the antibiotic. However, this stimulation is a transient
response to p-lactam antibiotics. Strains displaying constant AmpC derepression produce
higher amounts of p-lactamase, possibly due to the over expression resulting from
spontaneous mutations in regulatory genes (Livermore, 2002). Antibiotics such as
imipenem, benzylpenicillin, and cefoxilin are strong inducers, whereas newer P-lactam
antibiotics such as piperacillin are weak inducers under in vitro conditions (Giwercman et
al., 1990).
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Three genes related to peptidoglycan recycling are implicated in ampC
stimulation. These genes include ampD (encodes a cytosolic JV-acetyl-anhydromuramylZ-alanine amidase and specifically hydrolyzes 1,6-anhydromuropeptide), ampR (encodes
a transcriptional regulator of the LysR family), and ampG (functions as a permease for
1,6-anhydromuropeptide, the signal molecule for stimulation of ampC expression, and
encodes a transmembrane protein) (Langaee et al., 2000). Inactivation of AmpD results
in cytoplasmic buildup of 1,6-anhydromuropeptide and finally constitutive over
expression of AmpC (Langaee et al., 2000). In P. aeruginosa, three phenotypes of
distorted AmpC expression have been related to p-lactam resistance, and two out of three
have been related to mutations in the ampD gene (Langaee et al., 2000). AmpR and
AmpD regulators also control the inducible expression of the ampC gene (Langaee et al.,
2000).
Plasmid-encoded P-lactamases active against cephalosporins and penicillins may
provide a mechanism for P-lactam resistance (Giwercman et al., 1990, Lambert, 2002).
For newer stable P-lactam antibiotics, the rapid appearance of P-lactam resistance during
drug therapy and frequent therapeutic failures related to the expansion of multiple
resistances to P-lactam antibiotics are now common (Giwercman et al., 1990).

2.2. Multidrug efflux pumps
The combination of numerous resistance genes was first thought to be the
exclusive cause of multiple antibiotic resistances in bacteria, each encoding resistance to
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a separate drug. More recently, resistant phenotypes have been found to be due to the
activity of drug efflux pumps (Nikaido, 1998). Several of these efflux pumps reveal
broad ranges of specificity covering nearly all chemotherapeutic agents, inhibitors,
detergents, and antibiotics (the exemption possibly being highly hydrophilic complexes).
These efflux pumps work efficiently through their synergetic interaction with the outer
membrane barrier in some Gram-negative bacteria, including P. aeruginosa (Nikaido,
1998).
Three protein components make up the multidrug efflux system: an outer
membrane porin, an energy dependent pump positioned in the cytoplasmic membrane,
and a linker protein which couples these two membrane components. This tripartite
arrangement removes toxic molecules such as antibiotics that find their way into the
cytoplasmic membrane, the periplasm, or the cytoplasm (Lambert, 2002).
In P. aeruginosa four different efflux systems have been observed: MexABoprM, MexXY-oprM, MexCD-oprJ, and MexEF-oprN. The pump proteins MexB and
MexY are positioned in the cytoplasmic membrane, whereas MexA and MexX which are
so called "membrane fusion" proteins are anchored in the inner membrane, but extend to
the periplasm. Two of these pumps, MexXY-oprM and MexAB-oprM supply the
intrinsic resistance of wild-type strains to antibiotics. MexXY-oprM is responsible for
extrusion of aminoglycosides, whereas MexAB-oprM extrudes pMactams, quinolones,
and a large range of disinfectants (Lambert, 2002). The genes for these systems exist in
all strains of P. aeruginosa, but are not expressed in high amounts (Lambert, 2002).
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MexAB-oprM may lead to elevated antibiotic resistance in clinical strains when it is
expressed in high levels as a result of mutations that take place in the mexR regulatory
gene of the bacteria (Aires et al., 1999). The two other efflux pump systems, MexCDoprJ and MexEF-oprN are not constitutively formed in the wild-type strains of P.
aeruginosa. These efflux pumps are homologous to MexAB-oprM, and are more
substrate-restricted than MexAB-oprM. They are capable of accommodating complexes
as structurally diverse as trimethoprime, chloramphenicol, and quinolones. NficB and
mexT (nficC) are regulatory genes for MexCD-oprJ and MexEF-oprN, respectively.
Mutations that take place in these genes are also associated with higher levels of
antibiotic resistance (Aires et al., 1999).
MexY, homologous to AcrD in Escherichia coli, is related to a membrane fusion
protein MexX and serves as a drug proton anti-porter. Elevated levels of expression of
MexXY efflux system has been observed in few aminoglycoside resistant types of P.
aeruginosa, and has been illustrated as a major source of aminoglycoside resistance in
isolates collected from the lungs of CF patients (Islam et al., 2004). It has been suggested
that MexXY efflux pump system shares the OprM channel with MexAB, since it does not
have a gene for an outer membrane protein that should be located downstream of mexY.
The expression of MexXY is under negative regulation by another protein called MexZ.
This protein is encoded by a gene that is located 263 bp upstream of mexXand is
transcribed divergently. MexZ is thought to have a DNA-binding domain at its Nterminal that contains a helix-turn-helix motif. In wild-type P. aeruginosa isolates
deletion of MexXY increases their susceptibility to antibiotics such as erythromycin,
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tetracycline, and gentamycin. MexXY-oprM is also inducible by gentamycin and
tetracyclin antibiotics and has the ability to pump out fluoroquinolones, macrolides, and
carbapenems (Islam et al., 2004).

2.5. Mutational impermeability
In P. aeruginosa the outer membrane limits the rate of penetration of small
hydrophilic molecules and at the same time excludes larger molecules. The outer
membrane also serves as an important barrier to the penetration of antibiotics. P-lactams
and quinolones are small hydrophilic molecules which can only pass the outer membrane
through the aqueous channels supplied by porin proteins. Several different porins are
formed in P. aeruginosa. OprF is one of the major porins that is present in all strains of
P. aeruginosa. Although mutant strains lacking the OprF porin have been documented,
lack of this porin has not been reported to have a significant effect on antibiotic resistance
of the organism to any drugs, most probably because such strains have limited capability
to take up hydrophilic compounds (Lambert, 2002).
Resistance to imipenem and reduced susceptibility to meropenem is reported to be
associated with loss of OprD porin. OprD is a porin which shapes narrow
transmembrane channels and is only utilized by carbapenems but not other P-lactams.
OprD is co-regulated with Mex-EF-oprN. Therefore, the njxC (mexT) mutants that are
selected by antibiotics such as fluoroquinolones (but not carbapenems) have up-regulated
MexEF-oprN and lower OprD levels. These mutants subsequently have abridged
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susceptibility to meropenem and resistance to both imipenem and fluoroquinolones
(Livermore, 2002).

2.4. Alterations in penicillin-binding proteins
In P. aeruginosa alterations in penicillin-binding proteins are also related to Plactam resistance. The efflux pump system adds only weakly to P-lactam resistance
(caused by PBP mutations) most likely because the increased antibiotic buildup predicted
in the deletion copies is still inadequate to overcome the lowered affinity of the PBP for
p-lactams (Masuda et al., 2000).

2.5. DNA gyrase and topoisomerase TV mutations
The DNA gyrase is a holoenzyme which is a tetramer consisting of A and B
subunits. These subunits are products of gyrA and gyrB, respectively (Kureishi et al.,
1994). The DNA gyrase enzyme is a type II DNA topoisomerase responsible for
introducing negative superhelical coils into covalently attached DNA in a process that is
ATP-dependent (Kureishi et al., 1994). It also functions in DNA decatenation,
replication, and transcription regulation of some promoters that are supercoil sensitive
(Kureishi et al., 1994). The A subunits are in charge of DNA reunion and breakage, and
the B subunits are dedicated to ATP hydrolysis (Kureishi et al., 1994). DNA gyrase has
been proven to be a suitable target for antibiotics (Kureishi et al., 1994). Quinolones
such as ciprofloxacin and nalidixic acid inhibit the action of the A subunits while
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antibiotics such as coumermycin Al and novobiocin are known to inhibit the action of B
subunits (Kureishi et al., 1994). The glyeocinnamoylspermidine agent cinodine and
microcin (an antibiotic peptide) have also been reported to inhibit the function of the
DNA gyrase enzyme (Kureishi et al., 1994).
In most countries fluoroquinolones are the only accessible antibiotics for oral
treatment of infections caused by P. aeruginosa (Jalal et al., 2000). However, it easily
becomes resistant to these antibiotics, rigorously constraining their effectiveness.
Mutations in the target genes that encode DNA gyrase (gyrA) and topoisomerase IV
(parC) are the main mechanisms of resistance to fluoroquinolones (Jalal et al., 2000).
Mutational studies have shown that parC mutations in codon 80 (Ser—• Leu), and codon
84 (Glu—>Lys) have been associated with higher fluoroquinolone resistance (Nakano et
al., 1997). GyrA mutations in codon 83 (Thr—>Ile) and codon 87 (Asp—»Asn or
Asp—»Tyr) are associated with elevated fluoroquinolone resistance (Yonezawa et al.,
1995). Multiple mutations in both parC and gyrA genes in codons 80, 83, 84, and 87 are
linked to much more elevated resistance in P. aeruginosa (Mouneimne et al., 1999,
Nakano etal., 1997.)
A recent study on fluoroquinolone resistant P. aeruginosa (MI032) clinical
isolates have shown that gyrA mutations with an additional mutation in the mexR
regulatory gene leads to accelerated resistance. This signifies that antibiotic resistance
associated with DNA gyrase in general corresponds to efflux and gyrA mutations (Jalal et
al., 2000, Nakajima et al., 2002).
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2.6. P. aeruginosa biofilms and resistance
Creation of an alginate barrier is another resistance mechanism in P. aeroginosa.
P. aeruginosa grows in microcolonies enclosed in an alginate barrier composed of
various polysaccharides (Lambert, 2002). This kind of growth typifies biofilm (Lambert,
2002). Notable resistance to antibiotics is common to all biofilms (Lambert, 2002).
Although documented for many years, the complete biological events in bioflim
formation and antibiotic resistance are not well understood. Physical segregation of the
antibiotic and high bacterial concentration are factors that participate in the resistance of
bacteria in biofilm (Lambert, 2002). In general, reactions to physiological alterations
may arise in cells in the biofilm in which defensive mechanisms are provoked and key
metabolic pathways are shut down. It is apparent that cells in the biofilm can alter their
properties according to surrounding cells by sensing their presence (quorum sensing)
(Lambert, 2002). The biofilm consists of a heterogeneous population of cells, including
slow and fast growing cells. Some cells are resistant through production of efflux pumps
and inactivating enzymes, whereas others are not (Lambert, 2002). Therefore, the
general resistance relies on the interaction of the entire population, and therapies need to
be aimed against a community that is multicellular (Lambert, 2002).

2.7. Propositions for therapy
Efflux and restricted permeability are essential properties of the organism and are
crucial in developing resistant phenotypes to antibiotics as diverse as quinolones, p-
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lactams, and aminoglycosides. In other words, innate resistance results from the action of
efflux systems and restricted permeability of the cell wall, and may be enhanced by
elevated expression of special efflux pump systems (Lambert, 2002).
In CF patients, the incidence of more specific mechanisms which engage alteration
and inactivation in target molecules reflects the selective pressure due to reliance of these
patients to these drugs. For example, expression of chromosomal (3-lactamase can be
increased by spontaneous mutations in the chromosomal genes. These mutants are
chosen under the stress of antibiotic treatment especially when monotherapy is used.
Increased recognition of the role of efflux pumps in causing natural resistance to
antibiotics has resulted in the search for efflux pump inhibitors which could serve as
therapeutic adjuncts. Correspondingly, understanding of the multifaceted interaction in
biofilm populations may ultimately lead to developing novel therapeutic approaches.
However, P. aeruginosa has always adapted to antibiotic therapy. The threatening size of
its genome and the present lack of information of the role of many of its genes will
continue to be an important issue in developing novel therapies (Lambert, 2002).
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ABSTRACT
Excessive use of broad-spectrum antibiotics in hospitals has led to the emergence of
highly resistant strains of Pseudomonas aeruginosa. To reduce the selection pressure for
resistance, it is important to determine the antibiotic-susceptibility pattern of bacteria so
that hospital patients can be treated with more narrow-spectrum and target-specific
antibiotics. This study describes the development of a technique for detecting point
muations in the fluoroquinolone resistance-determining region of the gyrA and par-C
genes as well as the efflux regulatory genes mexR, mexZ, and mexOZ that are associated
with fluoroquinolone and aminoglycoside resistance. The assay is based on a short
DNA-sequencing method using multiplex-fast polymerase chain reaction (PCR) and
Pyrosequencing™ for amplification and sequencing of the selected genes. Fifty-nine
clinical isolates of P. aeruginosa were examined for mutations in the above-mentioned
genes. Mutations related to antibiotic resistance were detected in codons 83 and 87 of
gyrA and codon 126 of the mexR regulatory gene. Results of this study suggest
Pyrosequencing™ as a substitute for traditional methods, as it provides a rapid and
reliable technique for determining the antibiotic-resistance pattern of a given bacterial
strain in < 1 h.
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1. Introduction
The emergence of drug-resistant bacteria occurs frequently in the Intensive Care
Unit (ICU) involving both Gram-negative and Gram-positive organisms. This is a
problem for critical care physicians because there are now several pathogens that can
only be effectively treated with a limited number of antimicrobial agents, e.g.
methicillin-resistant Staphylococcus aureus (MRSA), Enterococcus faecium, and Gramnegative bacteria producing extended-spectrum P-lactamases (Kollef and Micek, 2005).
Multidrug-resistant (MDR) bacterial infections are associated with increased
mortality, length of hospital stay, and cost of care (Geissler et al., 2003). For example, in
a study from a large tertiary-care teaching hospital in Boston, MA, the median length of
stay and hospital charges were significantly greater for patients with MRSA compared
with those with methicillin-sensitive S. aureus.
Successful treatment of patients admitted to the ICU with nosocomial or
community-acquired infections depends on adequate initial antibiotic use. A common
strategy is to begin with broad-spectrum antibiotic therapy, and later to de-escalate
antibiotic therapy based upon culture and sensitivity data. Initial broad-spectrum therapy
is necessary until culture data are available to guide focused antibiotic administration.
However, broad-spectrum antibiotics are a leading cause of the emergence of drugresistant bacteria (Nseir et al., 2005).
Several strategies have been investigated as a means of reducing the emergence of
MDR bacteria in the ICU. One such strategy is to employ only narrow-spectrum
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antibiotics directed at pathogens identified using rapid bedside detection devices. This
strategy requires technology capable of detecting pathogens within minutes of sample
collection, pathogen identification and analysis of antibiotic resistance patterns, and
detection of organisms that may reside in the intracellular compartment.
One of the more common nosocomial pathogens is Pseudomonas aeruginosa
(Sherertz and Sarubbi, 1983). Excessive use of broad-spectrum antibiotics has led to the
emergence of highly resistant strains of P. aeruginosa that are a major threat to patients
in the ICU. Adequate treatment of P. aeruginosa infections with modern antibiotics is
difficult due to the intrinsic ability of the bacterium to adapt rapidly to new environments
and acquire resistance to common therapies (Lambert, 2002, Livermore, 2002).
Fluoroquinolones and aminoglycosides are two important classes of antibiotics
used in the treatment of Pseudomonas infections. Fluoroquinolones are members of the
quinolone family that act as bactericidal agents by inhibiting bacterial DNA gyrase and
topoisomerase IV, thereby inhibiting DNA transcription and replication. DNA gyrase is
typically the target in Gram-negative organisms, whereas topoisomerase IV is the target
in Gram-positive organisms. Aminoglycosides are a separate class of antibiotics that
bring about their bactericidal action by binding to the bacterial 30S ribosomal subunit,
inhibiting the translocation of the peptidyl-tRNA from the A-site to the P-site, causing
misreading of the mRNA and thus rendering the bacterium unable to synthesize proteins
vital to its growth. Pseudomonas readily develops resistance to these agents,
consequently reducing their utility. The main mechanisms of resistance are mutations in

19

the genes that encode DNA gyrase (gyrA) and topoisomerase IV (parC). Other
mechanisms include mutations in the regulatory genes of the multidrug efflux pumps,
mexAB-oprM and mexXY-oprAf (Jalal et al., 2000). The MexAB-oprM efflux system
contributes to the natural resistance of bacteria to a wide range of antibiotics including
fluoroquinolones, P -lactams, and P-lactamase inhibitors, whereas MexXY-oprM
contributes to aminoglycoside resistance. High expression of MexAB-oprM and
MexXY-oprM may confer high levels of resistance to clinical strains as a result of
mutations occurring mainly in their regulatory genes mexR and mexZ (Aires et al., 1999,
Islam et al., 2004). Another region related to aminoglycoside resistance is mexOZ, which
is an intergenic region between the mexZ and mexX genes of P. aeruginosa (Islam et al.,
2004).
In this study, we attempted to design a DNA-based technique for rapid
determination of the antibiotic-resistance pattern of P. aeruginosa compared with
traditional methods such as disk diffusion or agar dilution. Multiplex polymerase chain
reaction (PCR) and Sanger sequencing were used to find key mutations in the gyrA,
mexR, parC, mexZ, and mexOZ genes of P. aeruginosa isolates exhibiting resistance to
fluoroquinolones and aminoglycosides, and Pyrosequencing™ was used as the ultimate
sequencing method to detect specific point mutations in these genes.
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2. Materials and methods
2.1. Clinical isolates of P. aeruginosa
Fifty-nine previously identified clinical isolates of P. aeruginosa were obtained
from the Microbiology Laboratory at Stanford Hospital (Stanford, CA) to evaluate
mutations involved in antibiotic resistance. These isolates were previously tested by the
Kirby-Baur method for their susceptibility to fluoroquinolones and aminoglycosides.
Samples were accordingly assigned to one of three groups, i.e. resistant, intermediate or
susceptible to either fluoroquinolones or aminoglycosides. Fluoroquinolones and
aminoglycosides used in the antibiotic susceptibility tests were ciprofioxacin/levofloxacin
and tobramycin, respectively. Of the 59 clinical isolates, 12 were resistant, 6 were
intermediate, and 41 were susceptible to ciprofloxacin, levofloxacin or both (Table 1),
and 43 were susceptible, 4 were intermediate and 12 were resistant to tobramycin.

2.2. DNA extraction and multiplex PCR
DNA was extracted from the 59 clinical isolates of P. aeruginosa using the
Qiagen Kit (Qiagen, Valencia, CA) according to the manufacturer's instructions and was
used as the DNA template for multiplex/multiplex-fast PCR. Primers gyrA-1 (5'GTGTGCTTTATGCCATGAG-3') and gyrA-2 (5*-GGTTTCCTTTTCCAGGTC-3') were
used to amplify 287 bp of the fluoroquinolone resistance-determining region of the gyrA
gene. Primers parC-1 (5'-CATCGTCTACGCCATGAG-3') and parC-2 (5'AGCAGCACCTCGGAATAG-3') were used to amplify 267 bp of the fluoroquinolone

21

resistance-determining region ofparC. For the mexR regulatory gene, mexR-1 (51CTGGATCAACCACATTTACA -3') and mexR-2 (5'CTTCGAAAAGAATGTTCTTAAA-3') primers were used to amplify the whole 503-bp
region of the gene. Primers for amplification of gyrA, parC, and mexR were designed
with Primer 3 software (http://fokker.wi.mit.edu/primer3/input.htm), using known
sequences available in GenBank with accession numbers L29417, AB003428, and
U23763, respectively. The regulatory genes mexZ and mexOZ were amplified using
primers from published data (Islam et al., 2004). All primers were synthesized by
Integrated DNA Technologies (Coralville, IA).
PCR amplification was performed in a 50 ul mixture containing IX ThermoStart™ Buffer (ABgene, Rockford, IL), 2.5 mM MgCk, 0.2 mM mix of deoxynucleotide
triphosphates (Sigma-Aldrich, St Louis, MO), 10 pmole of each primer, 1U of ThermoStart DNA polymerase (ABgene), and 150 ng of the DNA template. Amplification of the
target regions was performed in 35 cycles consisting of initial heat activation at 95 °C for
15 min, denaturation at 95°C for 45 s, annealing at 51°C for 45 s, and elongation at 71°C
for 1 min, with a final elongation at 71 °C for 7 min. The PCR products obtained from
this step were used for Sanger sequencing.

2.3. Sanger sequencing
Dideoxy sequencing was performed using BigDye™ Terminator Chemistry v. 3.1
(Applied Biosystems, Foster City, CA) according to the manufacturer's instructions, as
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described previously (Gharizadeh et al., 2006). Forward and reverse primers for gyrA,
parC, mexR, mexZ, and mexOZ (Section 2.2) were used as sequencing primers using the
ABI 3730 Bioanalyzer (Applied Biosystems).

2.4. Multiplex-fast PCR
Two fluoroquinolone-resistant isolates with mutations both on gyrA and mexR
were chosen for multiplex-fast PCR. The primers used for amplification of gyrA and
mexR with the Veriti™ 96-Well Fast Thermal Cycler (Applied Biosystems) were
identical to those used in the traditional PCR (see Section 2.2). Forward gyrA and
reverse mexR primers were biotin-labelled for single-strand separation. Amplification of
the selected regions was performed in a 20 ul mixture with 2.5 mM MgCk, 0.2 mM mix
of deoxynucleotide triphosphates (Sigma-Aldrich), 10 pmole of each primer, 1U of
AmpliTaq Gold (Applied Biosystems), and 150 ng of the DNA template. Multiplex-fast
PCR was performed in 25 cycles as follows: initial heat activation at 95°C for 10 min,
denaturation at 95°C for 1 s, annealing at 46°C for 15 s, elongation at 72°C for 15 s, and
final elongation at 72°C for 30 s. PCR products obtained from this step were used for
Pyrosequencing™.

2.5. Sample preparation for Pyrosequencing™
Sample preparation for Pyrosequencing™ was performed according to the
manufacturer's instructions and as described previously (Gharizadeh et al., 2005).
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Single-stranded DNA amplicons were prepared semi-automatically, using a Vacuum Prep
Tool and Vacuum Prep Worktable (Biotage, Uppsala, Sweeden). A 10 ul aliquot of
biotinylated PCR products was immobilized onto 3 ul streptavidin-coated Sepharose™
High Performance Beads (Amersham Biosciences, Piscataway, NJ) by incubating at
42°C and agitation at 1400 rpm for at least 15 min in Eppendorf Thermomixer R
(Eppendorf AG, Hamburg, Germany). Double-stranded DNA immobilized on Sepharose
beads was washed with 70% ethanol and denatured with 0.2 M NaOH. Unbound singlestranded DNA was washed with 0.1 M TE buffer [0.1 M Tris HC1 (pH 7.6) containing 1
mM ethylene diamine tetra-acetic acid (EDTA)]. All the steps were performed according
to the manufacturer's instructions for the Vacuum Prep Station. The beads carrying
single-stranded DNA amplicons were suspended in 12 ul of annealing buffer [20 mM
Tris-acetate (pH 7.6), 2 mM Mg-acetate] containing 0.3 pmole sequencing primers. The
single-stranded DNA was annealed to the sequencing primer at 92°C for 2 min followed
by incubation for 5 min at room temperature.

2.6. Pyrosequencing™
Pyrosequencing™ (Biotage) was performed according to the manufacturer's
instructions as described previously (Gharizadeh et al., 2005). Single-stranded PCR
products were sequenced using a PSQ™ HS 96A System (Biotage). Sequencing was
preformed according to the manufacturer's instructions in a total volume of 12 ul using
PSQ™ 96 Gold Kit (Biotage).
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2.7. Cloning
PCR amplicons of gyrA were cloned using the TOPO TA Cloning ® Kit
(Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. Cloned
bacterial cells were cultured on LB medium (containing 10 g Bacto tryptone, 5 g Bacto
yeast extract and 10 g NaCl in 1 L of ddHiO) and incubated at 37°C. Isolated single
colonies from overnight cultures were suspended in 10 ul of water and incubated at 95 °C
for 10 min. Fragments harboring the gyrA regions were then amplified, using 10 pmol of
forward biotinylated gyrA primer, 10 pmol of reverse vector primer, and 10 ul of the cell
lysate containing the DNA template. Amplification of the cloned fragments was
performed using the same conditions as in Section 2.2.

3. Results
Fifty-nine clinical isolates of P. aeruginosa were examined for the occurrence of
mutations related to antibiotic resistance. Fragments of gyrA, parQ mexR, mexZ, and
mexOZ genes were amplified using multiplex PCR, and the efficacy of the amplification
was determined by gel electrophoresis. All fragments amplified adequately (data not
shown). The PCR samples were then analyzed for detection of point mutations in the
fluoroquinolone resistance-determining regions of gyrA and parC as well as the efflux
pump regulatory genes mexR, mexZ, and mexOZ, using the Sanger sequencing method.
To identify point mutations, sequences from clinical isolates were compared with that of
wild-type P. aeruginosa PAOl. Results from the molecular analysis were compared with
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the antibiotic-susceptibility profile of bacterial isolates to assess the correlation between
mutations and resistance (Table 1).

Table 1
Correlation between fluoroquinolone (ciprofloxacin/levofloxacin) susceptibility of 59 P.
aeruginosa clinical isolates and mutations in gyrA and mexR genes.
Mutations in gyrA (codon)

Mutations in mexR
(codon)

Mutations in parC

Mutations in mexZ and
mexOZ

Asp->Asn(87)

Val - • Qu (126)

None

Highly variable

Thr^Ile(83)
Asp->Tyr(87)

The results showed that among the 12 fluoroquinolone-resistant isolates, 4 had a
single mutation in gyrA, 4 had mutations both in gyrA and mexR and 4 had no mutations
in the sequence areas examined (Table 1). Mutations in mexZ and mexOZ genes were
highly variable within isolates, making it difficult to correlate a specific mutation with
aminoglycoside resistance. Therefore, mexZ and mexOZ genes were not further
evaluated using Pyrosequencing™.
Common mutations in fluoroquinolone-resistant strains occurred in codons 83 and
87 of the gyrA gene (Fig. 1). The nucleic acid alterations that occurred in these codons
changed the amino acid profile from Thr to He and Asp to Asn (or Asp to Tyr),
respectively, consistent with previous reports (Jalal et al., 2000, Nakano et al., 1997,
Yonezawa et al., 1995). No mutations were found inparC. A novel mutation related to
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fluoroquinolone resistance occurred in codon 126 of the mexR regulatory gene, changing
amino acid Val to Glu was detected (Fig. 2; Table 2).

Table 2
Mutations in gyrA, mexR, parC, mexZ, and mexOZ genes leading to amino acid
alterations.
Fluoroquinolone susceptibility
(no. of isolates)

Mutations in gyrA
only

Resistant (12)
Intermediate (6)
Suscpetible(41)

4
1
1

Mutations in mexR Mutations in both
only
gyrA and mexR
0
4
1
1
12
1

No mutations in
gyrA or mexR
4
3
27

To confirm the mutations related to fluoroquinolone resistance by
Pyrosequencing™, the PCR products amplified from all isolates were sequenced again
using a pre-programmed nucleotide dispensation, sequencing a 20-bp region starting 1
base upstream of the mutation site detected by the Sanger sequencing method. This preprogrammed sequencing was much more rapid and took only 20 min. Nucleotide
patterns of each isolate were compared with those of the wild-type P. aeruginosa PA01
for parts of the gyrA and mexR genes encoding amino acids 83, 87 and 126, respectively.
Absent or added sequence signal peaks were designated as mutations (Figs. 1 and 2). All
mutations detected by Sanger sequencing were confirmed by the Pyrosequencing™
method.
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Fig. 1. Pyrograms of the 20-bp sequence (amino acids 83-87) of the gyrA gene of P.
aeruginosa obtained by the pre-programmed DNA-sequencing method:
(a) the wild-type sequence of gyrA with no alterations; (b) nucleotide C —> A alteration in
codon 83; and (c) nucleotide G —• A alteration in codon 87. Arrows show the location
of point mutations in the signal peaks.

One isolate showed two peaks in a single nucleotide position that was expected to
be an absent peak or a peak representing either one of the existing nucleotides (A or C).
Because bacteria are haploid (one set of each gene), we suspected that this sample was a
mixed sample rather than a single isolate. Therefore, the sample was cloned using a TA
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Cloning Kit. The cloned fragments were amplified and further analyzed by
Pyrosequencing™. Pyrosequencing™ was performed using a five-cycle ACGT
nucleotide order dispensation. From the Pyrosequencing™ results, one-half of the
colonies showed no mutations and were considered as wild-type and one-half showed a
mutation. This confirmed that the sample had been a mixture, i.e. was contaminated by a
wild-type or a mutant of P. aeruginosa. Fig. 3 shows the sequencing results before and
after isolation of the sample by cloning.
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Fig. 2. Pyrograms of the 20-bp sequence of the mexR regulatory gene of P. aeruginosa
(amino acids 126-128) obtained by the pre-programmed DNA-sequencing method: (a)
the wild-type sequence of mexR with no alterations; and (b) nucleotide T —• A alteration
in codon 126. Arrows show the location of point mutations in the signal peaks.
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For amplification using multiplex-fast PCR, two fluoroquinolone-resistant isolates
with mutations both on gyrA and mexR were chosen and sequenced by
Pyrosequencing™. The results from the signal peaks were identical to the signal peaks
obtained by sequencing the amplicons from the multiplex PCR (data not shown).
Multiplex-fast PCR together with Pyrosequencing™ took < 1 h for detection of gyrA and
mexR mutations.
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Fig. 3. Pyrograms of the DNA sequence of gyrA for an isolate of P. aeruginosa, (a)
Sequencing data before cloning and isolation. The two arrows indicate the presence of
both A and C nucleotides in the sequence. The gyrA gene was cloned into a plasmid
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vector, amplified by polymerase chain reaction (PCR) and sequenced by
Pyrosequencing™ using a five- cycle ACGT dispensation, (b and c) pyrograms after
isolation of the mixed DNA sample; ca. 50% of the cloned vectors harbored DNA from
wild-type (c) and 50 % harbored DNA from a mutant of P. aeruginosa (b) (C —• A
alteration).

4. Discussion
Fluoroquinolone and aminoglycoside resistance can lead to treatment failure in P.
aeruginosa infections (Aires et al., 1999, Jalal et al., 2000). Known mutations
responsible for resistance are found in the genes expressing DNA gyrase, and
topoisomerase IV and in genes that regulate the expression of efflux pumps. These
mutations interfere with binding of these antibiotics to the target sites of the DNA gyrase
and topoisomerase IV, or lead to hyperextrusion of the drug by the bacterial efflux
pumps. Because traditional microbiological culturing is time-consuming, empirical
treatment is often started 18-24 h prior to definitive identification of the pathogen and 48h prior to knowledge of its susceptibility profile. To eradicate drug-resistant strains of P.
aeruginosa, it is crucial to design a molecular technique to identify resistance rapidly so
that these infections may be treated appropriately.
Rapid and reliable methods are needed for the detection of resistant organisms,
most of which can be identified through a limited number of mutations. Multiplex-fast
PCR together with Pyrosequencing™ provides the advantage of requiring lower sample
volumes, significantly reducing the cost of performing sequencing reactions. Multiplexfast PCR and DNA sequencing by Pyrosequencing™ using a pre-programmed
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sequencing approach, as outlined here, takes < 1 h, compared to other amplification and
sequencing methods that take up to 5 hours.
Notably, all the mutations detected by the Sanger sequencing method were
confirmed by the more efficient Pyrosequencing™ method. For gyrA, the main
mutations found to be related to fluoroquinolone resistance were on codons 83 and 87, as
previously reported (Jalal et al., 2000, Jalal and Wretlind, 1998, Nakano et al., 1997,
Yonezawa et al., 1995). We discovered a mutation in codon 126 of the mexR regulatory
gene, changing amino acid Val to Glu, which correlated with fluoroquinolone resistance.
Almost all the clinical isolates in this study that had a single mutation in mexR were
susceptible and did not show any drug resistance, indicating that a mexR mutation alone
may not change the susceptibility of the bacterium but causes resistance when it cooccurs with a mutation on the gyrA gene. The mutations found on gyrA and mexR were
also found in susceptible isolates, and not all resistant isolates had mutations on these
genes (Table 1). Our results show that detection of gyrA and mexR mutations does not
always imply resistance to fluoroquinolones, but that acquiring these mutations increases
the likelihood of resistance. These discrepancies suggest the existence of other additional
molecular mechanisms for fluoroquinolone resistance.
Pyrosequencing™ was also able to distinguish a mixed sample from other clinical
isolates. The pyrogram shows the presence of both A and C nucleotides at a single spot
location in part of the gyrA gene. This could only be explained by assuming that this
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sample was mixed since bacteria are haploid. Pyrosequencing™ results after cloning the
gyrA fragment confirmed this hypothesis.
In conclusion, point mutations in clinical isolates associated with antibiotic
resistance are rapidly and reliably detected by DNA-sequencing using Pyrosequencing™
and multiplex-fast PCR. With this novel approach, clinical isolates could be analyzed
quickly at lower cost. The panel of mutations screened can be readily expanded to cover
other known resistance determinants in P. aeruginosa, and to detect mutations involved
in a variety of antibiotic resistance scenarios. Rapid and simple detection of resistance
determinants at the genetic level could guide the choice of more appropriate antibiotics,
and enable effective employment of narrow-spectrum antibiotics. Ultimately, more
accurate diagnosis and treatment could lower the incidence of resistance, and improve
outcomes for patients with severe bacterial infections.
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GENERAL CONCLUSIONS
Opportunistic P. aeruginosa infection is a major problem in medical care. The
growing threat from resistant strains calls for development of accurate diagnostic
methods and effective treatment strategies. Recent studies have focused on molecular
mechanisms of antibiotic resistance and genetic parameters involved in development,
acquisition, and spread of resistance genes. Reports have demonstrated several molecular
mechanisms of antibiotic resistance. Understanding the distribution and combinations of
genetic resistance mechanisms will contribute to identify potential targets for new
antibiotics, and developing better diagnostic tools and treatment strategies to meet the
challenges of P. aeruginosa infection.
In this study, a new molecular approach using DNA-sequencing methods
(Pyrosequencing™ and multiplex-fast PCR), clinical isolates of P. aeruginosa were
analyzed quickly for point mutations leading to resistance to current antibiotics. The
method described in this study, can be readily expanded to cover a variety of known
resistance determinants in P. aeruginosa. This technique could also be used as a general
approach for mutation detection in other microbial resistance studies. Rapid and simple
determination of resistance determinants at the genetic level could guide the choice of
more appropriate antibiotics, and enable the development of narrower spectrum
antibiotics. Ultimately, more accurate diagnosis and treatment could lower the incidence
of resistance, and improve outcomes for patients with severe bacterial infections.
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In this study, we designed a molecular technique for rapid, easy, and costeffective diagnosis of antibiotic resistance in clinical isolates of P. aeruginosa that can
have application in epidemiological studies, and developing and implementing strategies
for infectious diseases. Further investigation on larger numbers of isolates collected from
different medical centers will be required. These isolates should include resistant as well
as susceptible strains with their relevant susceptibility profiles which could not be
validated in this preliminary study. Epidemiological data indicating the patient's status
and the type of infectious diseases not included in this study will be helpful in
interpreting the results.
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APPENDIXES
APPENDIX A. SUMMARY OF DNA-SEQUENCING RESULTS
Table 1A. GryA,parC, mexR mutations, and fluoroquinolone susceptibility of P.
aeruginosa clinical isolates.
Sample ID

gyrA Mutations parC Mutations mexR Mutations

M583111
M586966
M587161
M586030
W607182
M586970
M581880

none
none
none
none
none
none
none

none
none
none
none
none
none
none

M586981

none

none

F598875
T613503-1
T613503-2
T613898-2
T614089-2
F597588-1
F597588-3
F596760-3
F596760-2
T614204-2
T614052-1
T612031-1
T612031-2
T613324-3
T613324-2
T614084-1
T614084-2
H605658-1
M595294-2

none
none
none
none
none
none
none
none
none
none
none
none
none
none
none
none
none
(87) Asp->Asn
none

none
none
none
none
none
none
none
none
none
none
none
none
none
none
none
none
none
none
none

none
(126) Val-»Glu
(126) Val-^Glu
none
none
none
none
(79) Asn-^Ser
(126) Val-^Glu
none
none
none
(132)Val-*Ala
(126) Val-^Ghi
none
none
(126) Val-^Glu
none
none
none
none
none
(126) Val-^Glu
none
none
none
none
(126) Val-^Ghi
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fluoroquinolone
Susceptibility
susceptible
susceptible
susceptible
susceptible
susceptible
susceptible
susceptible
susceptible
susceptible
susceptible
susceptible
susceptible
susceptible
susceptible
susceptible
susceptible
susceptible
susceptible
susceptible
susceptible
susceptible
susceptible
susceptible
susceptible
intermediate
susceptible
susceptible

W618073 (87) Asp->Tyr

none

F615319
none
none
F618171
none
X360656
M628794
none
none
H640
W643857
none
none
F644797
H638643-3 (87) Asp->Tyr
F35726-2
none

none
none
none
none
none
none
none
none
none

(132)Val->A]a
(126) Val-^Gki
none
none
(126) Val-^Gki
none
none
(126) Val-^Ghi
(126) Val-*Glu
none
(126) Val-^Glu

H638643-2 (87) Asp->Tyr

none
none
none
none
none
none
none
none
none
none
none
none
none
none

none
none
(126)Val-»Glu
none
none
(126) Val-^Glu
none
none
(126) Val-»Glu
none
none
(126) Val-^Ghi
(126)Val-+Glu
none

H638636
F624989
M674446-2
M674446-1
H682001-5
F676239-6
F676239-5
M665266-1
F660729-2
H663398
T682138-4
M665266-2
F660729-1

none
none
none
none
(83) Thr-»Ife
none
none
(83) Thr-^Ile
none
(83) Thr-»Ife
(83) Thr^Ile
(83) Thr-*Ile
none
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susceptible
susceptible
susceptible
susceptible
susceptible
susceptible
susceptible
intermidiate (levofloxacin)
intermidiate (levofloxacin)
susceptible
resistant
intermidiate (levofloxacin)
susceptible
resistant
resistant
intermediate
intermediate
susceptible
resistant
susceptible
resistant
resktant
resistant
susceptible

Table IB. MexZ and mexOZ mutations, and tobramycin susceptibility of P. aeruginosa
clinical isolates.
Sample ID

mexZ Mutations

mexOZ Mutations

M583111

no amplification
(138)Leu->-Arg
(186) Asn—+ser
no amplification
none
none
none
none
no amplification
none
Insertion (frame shift)
(95) Glu-^Stop
none
(138)Leu—Arg
(186) Asn—•ser
(58) Val->Ala
Deletion (frame shift)
Deletion (frame shift)
none
none
Deletion (frame shift)
(131)Lys—Arg
(131)Lys->Stop
(131)Lys^Stop
Deletion (frame shift)
none
Deletion (frame shift)
(191)Met->Arg
(163)Leu->Pro
none
(46) Gry-»Cys
Deletion (frame shift)

295, 459 bps

susceptible

295,459 bps

susceptible

244bp
244 bp
Insertion (frame shift)
244, 358 bps
244 bp
199,229,268,415
244bp
244 bp
244 bp
244, 302 bps

susceptible
susceptible
susceptible
susceptible
susceptible
susceptible
susceptible
susceptible
susceptible

295,459 bps

susceptible

244 bp
244 bp
244, 274 bps
244, 274 bps
none
244 bp
none
none
244 bp
244 bp
244 bp
244 bp
244 bp
244 bp
244,201 bps
244 bp

susceptible
susceptible
susceptible
susceptible
susceptible
susceptible
susceptible
susceptible
susceptible
susceptible
susceptible
intermediate
susceptible
susceptible
resistant
susceptible

M586966
M587161
M586030
W607182
M586970
M581880
M586981
F598875
T613503-1
T613503-2
T613898-2
T614089-2
F597588-1
F597588-3
F596760-3
F596760-2
T614204-2
T614052-1
T612031-1
T612031-2
T613324-3
T613324-2
T614084-1
T614084-2
H605658-1
M595294-2
M647759
W670409-2

40

Tobramycin Susceptibility

W670409-3
F660729
H663398-3
T660514
F624989
H649427
W618073
F615319
F618171
X360656
M628794
H640927
W643857
F644797
H638643-3
F35726-2
H638643-2
H638636
F624989
M674446-2
M674446-1
H682001-5
F676239-6
F676239-5
M665266-1
F660729-2
H663398
T682138-4
M665266-2
F660729-1

Deletion (Same shift)
Deletion (frame shift)
none
none
Deletion (frame shift)
none
no amplification
none
none
(138)Leu->Arg
(186)Asn->Ser
none
Deletion and insertions
(frame shift)
Deletion (frame shift)
none
no alignment
none
(144)Ak->Val
none
Deletion (frame shift)
none
none
(138)Leu—Arg
(186) Asn-*Ser
(62) Met-+Lys
(62)Met-+Lys
(138) Leu-*Arg
(209)Asp->Gry
none
no alignment
no alignment
none

244 bp
no amplification
244 bp
244 bp
295,459 bps
244, 324 bps
244 bp
244 bp
none

susceptible
resistant
resisant
resistant
susceptible
intermediate
susceptible
susceptible
susceptible

295,459 bps

susceptible

244,453 bps

susceptible

none

susceptible

244, 358 bps
244 bp
244,277 bps
244,489 bps
244 bp
244 bp
295,459 bps
244 bp
244 bp

susceptible
intermediate
susceptible
susceptible
susceptible
susceptible
susceptible
resistant
resistant

295, 335,459 bps

resistant

244,489 bps
244,489 bps
295,459 bps
no amplification
244 bp
295,459 bps
295,459 bps
no ampHication

resistant
resistant
intermediate
susceptible
resistant
resisant
resistant
susceptible
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APPENDIX B. AGAROSE GEL ELECTROPHORESIS RESULTS

Low range
mexZ
ladder

Low range
ladder
mexOZ

P. aeruginosa mexOZ (382 bp) and mexZ (594bp)
PCR product
Figure 1A and IB. Agarose gel electrophoresis (1.5%) results of P. aeruginosa PCR
products using mexOZ and mexZ primers.
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Low range
ladder

gyrA

parC

mexR

P. aeruginosa gyrA (287bp), parC (267bp),
and mexR (503bp) PCR product
Figure 2. Agarose gel electrophoresis (1.5%) result of P. aeruginosa PCR products
using gyrA, parC, and mexR primers.
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